Covering Regulation, Indian Pharmacopoeia, APTA, Banking Resilience, Regulatory Sandbox. Explore critical updates in Regulation, Indian Pharmacopoeia, APTA trade, Banking Resilience, and the Regulatory Sandbox, highlighting advances in banking supervision, trade agreements, AI ethics, and drug standards enforcement.
Regulatory news, updates, and insights for India presented by the Carver Agents team
Welcome to Carver's India Regulatory Updates for June 07, 2026.
The Reserve Bank of India has emphasized resilience by design in the country's banking sector, as outlined by Swaminathan J. The approach focuses on transparent stress recognition, strengthening balance sheets, stronger supervision, adaptive regulation, and embedding resilience within banks. Key requirements include timely recognition and transparent reporting of asset quality stress, coordinated policy actions such as recapitalisation and resolution frameworks, and holistic, risk-based, forward-looking supervision covering governance, conduct, technology, and emerging risks. This initiative supports the adoption of calibrated and adaptive regulatory frameworks, including scale-based and tier-based regulations, to reduce systemic risk and enhance economic stability.
In trade news, the Asia-Pacific Trade Agreement, which includes India alongside Bangladesh, China, Lao PDR, Republic of Korea, and Sri Lanka, has reinforced preferential trade arrangements among developing countries. The agreement covers tariff concessions, border charges, non-tariff measures, and special concessions for least developed countries. Participating states are required to apply tariff, border charge, and non-tariff concessions according to their National Lists of Concessions, with a gradual relaxation of non-tariff measures affecting imports. This update aims to stimulate economic growth, investment, and employment while ensuring transparency and mutual benefits in international trade.
The Reserve Bank of India has also announced the Niveshak Shivir event held on June 5, 2026, in Bhopal, Madhya Pradesh. This event introduced the Internet of Regulated Services initiative, or IoRS, which involves multiple regulators collaborating on sandbox testing. FAQs were issued on the Cybersecurity and Cyber Resilience Framework and cloud adoption framework for Securities and Exchange Board of India regulated entities. Entities interested in participating in IoRS must apply via a single application to the Coordination Group hosted by RBI. Eligibility and net worth criteria follow the Principal Regulator’s sandbox framework. There is no application fee for IoRS, though sandbox fees may apply as per the Principal Regulator.
In the field of artificial intelligence, the Reserve Bank of India has constituted the Framework for Responsible and Ethical AI Committee, known as the FREE-AI Committee. This committee has formulated seven core principles, called Sutras, and 26 recommendations to guide AI adoption in the financial sector. These include infrastructure development, policy formulation, capacity building, governance, consumer protection, and cybersecurity enhancements. Key requirements include establishing shared infrastructure for data and compute democratization, creating an AI Innovation Sandbox, and developing indigenous financial sector-specific AI models. This framework aims to ensure that AI-driven innovation does not compromise safety and trust.
Finally, the Indian regulatory authorities have released detailed Frequently Asked Questions clarifying the authoritative and legal status of the Indian Pharmacopoeia, the role of the Indian Pharmacopoeia Commission, compliance requirements for drug products, the use of alternative analytical methods, and procedures for monograph development and reference substances. Compliance with Indian Pharmacopoeia standards is mandatory from the effective date mentioned in each monograph. Manufacturers may adopt published monographs early in consultation with regulatory authorities. Alternative analytical methods require validation and regulatory approval. This update reduces ambiguity and supports consistent enforcement of drug standards in India.
That wraps up today's regulatory updates. Visit carveragents.ai for more information.